- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Shalin Naik
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Mark Eaton
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor Daniel Gray
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marco Herold
- Professor Marnie Blewitt
- Professor Matthew Ritchie
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Czabotar
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sandra Nicholson
- Professor Sant-Rayn Pasricha
- Professor Seth Masters
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Atopic dermatitis causes and treatments
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Development of novel RNA sequencing protocols for gene expression analysis
- Discoveries in red blood cell production and function
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Ashley Weir
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jasmine Rou
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Krishneel Prasa
- Lilly Backshell
- Malvika Kharbanda
- Megan Kent
- Naomi Jones
- Pailene Lim
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Sophie Collard
- Wayne Cawthorne
- Wil Lehmann
- Yanxiang Meng
- Zhong Yan Gan
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
COVID-19 vaccine information
WEHI’s joint head of Infectious Diseases and Immune Defence Professor Marc Pellegrini answers some popular questions about the COVID-19 vaccine rollout in Australia.
FAQs
-
Does the Vaxzevria (AstraZeneca) COVID-19 vaccine cause blood clots?
-
Should I have the vaccine if I am pregnant, planning on becoming pregnant, or breastfeeding?
-
Can I have the COVID-19 vaccine if I have recently had the flu vaccine?
-
Will the vaccine last forever or will I have to be re-vaccinated in the future?
Which COVID-19 vaccines are being used in Australia?
The Therapeutic Goods Administration (TGA) has approved the Vaxzevria (AstraZeneca) vaccine, the Comirnaty (Pfizer) and the Spikevax (Moderna) vaccine for use in Australia.
The national roll-out of vaccines in Australia began in February 2021.
Why should I get vaccinated?
COVID-19 can spread quickly and widely. It has resulted in the deaths of more than 3.7 million people worldwide and more than 900 people in Australia. Vaccines strengthen your immune system by training it to quickly remember and fight specific germs. Vaccination is the most effective way to protect yourself against getting COVID-19, and also reduce the severity of the disease if you do contract it.
When you get vaccinated, you are protecting yourself and helping to protect the whole community.
Can I choose which vaccine I get?
The Australian Government has received expert advice from public health and vaccination specialists, including the Australian Technical Advisory Group on Immunisation (ATAGI). Based on this advice, recommendations have been made about which vaccines should be used depending on age and other risk factors. Vaccine roll-out and administration is aligned with these recommendations. The best person to discuss this with is your doctor.
Are the vaccines safe?
All vaccines are thoroughly tested before they are approved for use in Australia by the TGA, this includes rigorous assessment of the vaccine’s safety, quality and effectiveness. The TGA will continue to closely monitor for suspected side effects (also known as adverse events) from the use of COVID-19 vaccines. This includes careful analysis of clinical trial data, ingredients, chemistry, manufacturing and other factors. Additionally, ATAGI will regularly update their advice to the Australian Government about the risks and benefits of vaccines as new data becomes available.
If you have any questions about the vaccine and your personal health circumstances, you should consult with your doctor or healthcare professional.
Are the vaccines effective?
All vaccines used in Australia have a proven ability to decrease severe COVID-19 and death by about 80 per cent after a single injection. After a second injection, the protection afforded by these vaccines is even higher. There is some variability in the effectiveness of vaccines but after a complete course of COVID-19 vaccines, protection from infection ranges from 80-90 per cent. This figure is dependent on many factors, including the viral variants that are circulating. Regardless, there is clear evidence that the vaccines earmarked for use in Australia are already working very well to slow down the transmission of the virus in other countries.
Are there any side effects from the vaccine?
All vaccines have potential side effects. The vaccines used in Australia to immunise people against COVID-19 do have side effects. Side effects such as a soreness at the injection site or a mild illness can occur. There are some very rare but serious side effects such as allergies with Comirnaty (Pfizer) vaccine and a very rare clotting problem associated with the Vaxzevria (AstraZeneca) vaccine. Doctors have become very good as managing and treating these side effects such that the benefit of the vaccines greatly outweighs the risks of side effects.
Does the Vaxzevria (AstraZeneca) COVID-19 vaccine cause blood clots?
There has been a link established between the Vaxzevria (AstraZeneca) vaccine and a very rare but serious side effect called Thrombosis with Thrombocytopenia Syndrome (TTS).
There is a very low chance of this side effect. The Australian Technical Advisory Group on Immunisation (ATAGI) continues to review risk estimates as new data becomes available and update advice as required.
Fortunately, diagnosis and treatment for TTS has progressed rapidly. Doctors now know the symptoms to look out for, and haematologists have identified treatments for the condition. These include intravenous immunoglobulin (a concentrate of antibodies from healthy donors) and blood thinners.
There’s no evidence people who have previously experienced blood clots, have an inherited risk of blood clots, or who take blood thinners or related medications, have any increased risk of TTS.
To read more about this topic from one of our experts, read Associate Professor Sant-Rayn Pasricha's article in The Conversation:
Will I be monitored for side effects?
When you are vaccinated, your doctor will usually ask you to wait for 15-30 minutes afterwards, just in case you have an adverse reaction to the vaccine. If you experience any symptoms once you’ve gone home, particularly headaches or stomach pains, you should contact your doctor.
Should I have the vaccine if I have an allergy?
This is something people need to discuss with their doctor, who will assess the situation on a case-by-case basis. But generally speaking, there are no common allergies that should prevent you having a COVID vaccine.
With new vaccines it is critical to evaluate the safety after the vaccine has been licensed. Widespread use of COVID-19 vaccines suggests that severe allergic reactions to the Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) vaccines are very rare.
Should I have the vaccine if I am pregnant, planning to become pregnant or breastfeeding?
The Australian Technical Advisory Group on Immunisation (ATAGI) recommends that pregnant women are routinely offered the Comirnaty (Pfizer) vaccine at any stage of pregnancy. This is because the risk of severe outcomes from COVID-19 is significantly higher for pregnant women and their unborn baby.
Pregnant women are encouraged to discuss the decision in relation to the timing of vaccination with their doctor.
There is no evidence that women who become pregnant after being vaccinated against COVID-19 have an increased risk of developing complications that affect their pregnancy or their baby’s health. Getting vaccinated before conceiving means you are likely to have protection against COVID-19 throughout your pregnancy.
If you are breastfeeding, you can receive a COVID-19 vaccine at any time. You do not need to stop breastfeeding before or after vaccination.
For more information about the COVID-19 vaccine in relation to pregnancy see the statement on the Department of Health's website.
Will children and adolescents be vaccinated?
Children aged 5 to 11 years will be eligible for the paediatric Comirnaty (Pfizer) vaccine from January 2022. The paediatric vaccine will be one third of the dose given to people aged 12 and over.
For more information about the COVID-19 vaccine in relation to children age 5 to 11 see the statement on the Department of Health’s website
Adolescents aged 12 years and older are eligible to receive the Comirnaty (Pfizer) or the Spikevax (Moderna) COVID-19 vaccine.
There is high level evidence indicating strong immune response and vaccine efficacy against symptomatic COVID-19 in adolescents from clinical trials of the Comirnaty (Pfizer) and Spikevax (Moderna) vaccines.
For more information about the COVID-19 vaccine in relation to children see the statement on the Department of Health's website.
How many doses of the vaccine will I receive?
Each of the COVID-19 vaccines approved in Australia require a minimum of two doses. It is important for everyone to receive all the recommended doses for their age bracket to ensure maximum protection.
For individuals 5 to 11 years, the two doses of the Comirnaty (Pfizer) vaccine need to be given eight weeks apart.
For individuals 12 years and older the two primary doses of the Comirnaty (Pfizer) vaccine need to be given between 21 and 42 days apart.
The two primary doses of the Vaxzevria (AstraZeneca) vaccine should be given 12 weeks apart.
The two primary doses of the Spikevax (Moderna) vaccine should be given 28 days apart.
Will I need a booster dose?
Booster doses are recommended for individuals aged 18 years and over who have received their primary course of COVID-19 vaccine at least four months ago.
The Comirnaty (Pfizer) vaccine and the Spikevax (Moderna) have been approved by the TGA and recommended by ATAGI as a booster dose. For more information about booster doses read the statement on the Department of Health’s website
Can I have the COVID-19 vaccine if I have recently had the flu vaccine?
The COVID-19 vaccine does not protect against the flu, so you should still have a flu shot. It is recommended people wait at least 14 days between a dose of the seasonal flu vaccine and a dose of the Comirnaty (Pfizer), the Vaxzevria (AstraZeneca) or the Spikevax (Moderna) COVID-19 vaccine (or vice versa).
Talk to your doctor about any other vaccines you are having or have recently had when booking in for the COVID-19 vaccine.
Will the vaccine last forever or will I need to be re-vaccinated in the future?
It is possible that the immunity from vaccination might last a year or longer but at the moment it’s unclear. People may need to be re-vaccinated at some stage in the future.
I’ve had COVID-19, do I still need to be vaccinated?
Yes, even if you have had COVID-19, you should still be vaccinated. We still don’t know how long immunity to COVID-19 lasts. If you have had COVID-19, a vaccine will likely boost your immune responses further, and it is important to receive both doses of vaccine for maximum protection.
Should people with immune conditions be vaccinated?
People with immune conditions should still be vaccinated. But, along with all people who take anti-TNF treatments or any sort of immune suppressant, they need to be aware that vaccines may not be as effective.
It is important that people continue their regular treatment for immune conditions because otherwise they could become quite sick. People who are immunosuppressed have a higher risk of developing COVID-19, so it is important these people are vaccinated. Treatments should not be stopped for vaccination. While COVID-19 vaccination may provide a lower level of protection for people on immunosuppressive drugs, it will offer some protection.
If you have an immune condition, please talk with your doctor or specialist about the COVID-19 vaccine. More information for people with allergy, immunodeficiency, autoimmunity can be found at the Australasian Society of Clinical Immunology and Allergy.
To read more about this topic from one of our experts, read Dr Vanessa Bryant's article in The Conversation:
Are COVID-19 vaccines free?
Yes, COVID-19 vaccines are free for everyone in Australia.
Is the COVID-19 vaccine mandatory?
No, the Australian Government has stated that the COVID-19 vaccination is not mandatory. Vaccination against COVID-19 may become a requirement for travel to certain destinations or for people working in high-risk workplaces.
Further information:
Information last updated 4 January 2022